Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 6729 - 6736 of 12092 results
DTSA Does Not Create a Private Civil Cause of Action for Conspiracy to Commit Trade Secret Theft
September 25, 2017| Blog| Viewpoint
Federal Circuit Clarifies Venue Requirement Post-TC Heartland by Granting Mandamus Relief in In re Cray
September 25, 2017| Blog| Viewpoint
Building a Health App? Part 2: Protecting Your Intellectual Property
September 25, 2017| Blog| Viewpoint
Mass. Digital Health Developments: What To Know Now
September 22, 2017| News
Evolution of Repeal and Replace
September 22, 2017| Advisory| Viewpoint
Tesla Bringing Supercharger Stations to Boston and Chicago
September 21, 2017| Blog| Viewpoint
Calculating Patent Term Adjustment: Part 2
September 21, 2017| Blog| Viewpoint
New Jersey Supreme Court Reminder - Don’t Forget about the Corporate Practice of Medicine
September 21, 2017| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|